Polymorphisms in metalloproteinase-9 are associated with the risk for asthma in Mexican pediatric patients

Human Immunology

Volumn 74, Issue 8, 2013, Pages 998-1002

  Jiménez Morales, Silvia ^a   Martínez Aguilar, Nora ^b   Gamboa Becerra, Roberto ^a   Jiménez Ruíz, Juan Luis ^a   López Ley, Diana ^a   Lou, Hong ^c   Saldaña Alvarez, Yolanda ^a   Dean, Michael ^d   Orozco, Lorena ^a  

^a INSTITUTO NACIONAL DE MEDICINA GENÓMICA   (Mexico)

^b Hospital Pediátrico de Coyoacan SS   (Mexico)

^c SAIC FREDERICK INC   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; MESSENGER RNA; TRANSCRIPTION FACTOR;

ADOLESCENT; ALLERGIC ASTHMA; ARTICLE; ASTHMA; BINDING SITE; CHILD; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE SEVERITY; ETHNICITY; EXON; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HISPANIC; HOMOZYGOTE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MEXICO; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ALLELES; ASTHMA; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MEXICO; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK;

EID: 84879884627     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2013.04.036     Document Type: Article

References (53)

1. Amǎlinei C., Cǎruntu I.D., Giuşcǎ S.E., Bǎlan R.A. Matrix metalloproteinases involvement in pathologic conditions. Rom J Morphol Embryol 2010, 51:215-228.
2. Atkinson J.J., Senior R.M. Matrix metalloproteinase-9 in lung remodeling. Am J Respir Cell Mol Biol 2003, 28:12-24.
3. Mott J.D., Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 2004, 16:558-564.
4. Shapiro S.D., Senior R.M. Matrix metalloproteinases. Matrix degradation and more. Am J Respir Cell Mol Biol 1999, 20:1100-1102.
5. Parks W.C., Shapiro S.D. Matrix metalloproteinases in lung biology. Respir Res 2001, 2:10-19.
6. Demedts I.K., Brusselle G.G., Bracke K.R., Vermaelen K.Y., Pauwels R.A. Matrix metalloproteinases in asthma and COPD. Curr Opin Pharmacol 2005, 5:257-263.
7. Mori S., Pawankar R., Ozu C., Nonaka M., Yagi T., Okubo K. Expression and Roles of MMP-2, MMP-9, MMP-13, TIMP-1, and TIMP-2 in Allergic Nasal Mucosa. Allergy Asthma Immunol Res 2012, 4:231-239.
8. Winkler M.K., Foldes J.K., Bunn R.C., Fowlkes J.L. Implications for matrix metallopro teinases as modulators of pediatric lung disease. Am J Physiol Lung Cell Mol Physiol 2003, 284:L65-L557.
9. Chen L., Nakai M., Belton R.J., Nowak R.A. Expression of extracellular matrix metalloproteinase inducer and matrix metalloproteinases during mouse embryonic development. Reproduction 2007, 133:405-414.
10. Mehra D., Sternberg D.I., Jia Y., Canfield S., Lemaitre V., Nkyimbeng T., et al. Altered lymphocyte trafficking and diminished airway reactivity in transgenic mice expressing human MMP-9 in a mouse model of asthma. Am J Physiol Lung Cell Mol Physiol 2011, 300:L149.
11. Bratcher P.E., Weathington N.M., Nick H.J., Jackson P.L., Snelgrove R.J., Gaggar A. MMP-9 cleaves SP-D and abrogates its innate immune functions in vitro. PLoS One 2012, 7:e41881.
12. Izbicka E., Streeper R.T., Michalek J.E., Louden C.L., Diaz A., Campos D.R. Plasma biomarkers distinguish non-small cell lung cancer from asthma and differ in men and women. Cancer Genomics Proteomics 2012, 9:27-35.
13. Wang L.F., Chien C.Y., Chiang F.Y., Chai C.Y., Tai C.F. Corelationship between matrix metalloproteinase 2 and 9 expression and severity of chronic rhinosinusitis with nasal polyposis. Am J Rhinol Allergy 2012, 26:e1-e4.
14. Beeh K.M., Beier J., Kornmann O., Buhl R. Sputum matrix metalloproteinase-9, tissue inhibitor of metalloprotinease-1, and their molar ratio in patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and healthy subjects. Respir Med 2003, 97:634-639.
15. Cundall M., Sun Y., Miranda C., Trudeau J.B., Barnes S., Wenzel S.E. Neutrophil-derived matrix metalloproteinase-9 is increased in severe asthma and poorly inhibited by glucocorticoids. J Allergy Clin Immunol 2003, 112:1064-1071.
16. Hong Z., Lin Y.M., Qin X., Peng J.L. Serum MMP-9 is elevated in children with asthma. Mol Med Report 2012, 5:462-464.
17. Kelly E.A., Busse W.W., Jarjour N.N. Increased matrix metalloproteinase-9 in the airway following allergen challenge. Am J Respir Crit Care Med 2000, 162:1157-1161.
18. McMillan S.J., Kearley J., Campbell J.D., Zhu X.W., Larbi K.Y., Shipley J.M., et al. Matrix metalloproteinase-9 deficiency results in enhanced allergen-induced airway inflammation. J Immunol 2004, 172:2586-2594.
19. Oshita Y., Koga Kamimura T., Matsuo K., Rikimaru T., Aizawa H. Increased circulating 92kDa matrix metalloproteinase (MMP-9) activities in exacerbations of asthma. Thorax 2003, 58:757-760.
20. Nakashima K., Hirota T., Obara K., Shimizu M., Doi S., Fujita K., et al. A functional polymorphism in MMP-9 is associated with childhood atopic asthma. Biochem Biophys Res Commun 2006, 344:300-307.
21. Ganter K., Deichmann K.A., Heinzmann A. Association study of polymorphisms within matrix metalloproteinase 9 with bronchial asthma. Int J Immunogenet 2005, 32:233-236.
22. Lose F., Thompson P.J., Duffy D., Stewart G.A., Kedda M.A. A novel tissue inhibitor of metalloproteinase-1 (TIMP-1) polymorphism associated with asthma in Australian women. Thorax 2005, 60:623-628.
23. Pinto L.A., Depner M., Klopp N., Illig T., Vogelberg C., von Mutius E., et al. MMP-9 gene variants increase the risk for non-atopic asthma in children. Respir Res 2010, 11:23.
24. Jiménez Morales S, Velázquez Cruz R, Ramírez-Bello J, Bonilla-González E, Romero- Hidalgo S, et al. Tumor necrosis factor-α is a common genetic risk factor for asthma, juvenile rheumatoid arthritis, and systemic lupus erythematosus in a Mexican pediatric population. Hum Immunol 2009;70:251-6.
25. Sadeghi M., Motovali-bashi M., Hojati Z. MMP-9 promoter polymorphism associated with tumor progression of breast cancer in Iranian population. Int J Integ Biol 2009, 6:33-37.
26. Cong Y., Guo X., Liu X., Cao D., Jia X., Xiao X., et al. Association of the single nucleotide polymorphisms in the extracelular matrix metalloprotease-9 gene PACG in Southern China. Mol Vis 2009, 15:1412-1417.
27. Yuan HY, Chiou JJ, Tseng WH, Liu CH, Liu CK, Lin YJ, et al. FASTSNP: an always up -to-date and extendable service for SNP function analysis and prioritization. Nucleic Acids Res 2006; 34(Web Server Issue):W635-W641.
28. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
29. Van Lint P., Libert C. Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. J Leukoc Biol 2007, 82:1375-1381.
30. Wolf M., Albrecht S., Märki C. Proteolytic processing of chemokines: implications in physiological and pathological conditions. Int J Biochem Cell Biol 2008, 40:1185-1188.
31. Bosse M., Chakir J., Rouabhia M., Boulet L.P., Audette M., Laviolette M. Serum matrix metalloproteinase-9: tissue inhibitor of metalloproteinase-1 ratio correlates with steroid responsiveness in moderate to severe asthma. Am J Respir Crit Care Med 1999, 159:596-602.
32. Bradley L.M., Douglass M.F., Chatterjee D. Matrix metalloprotease 9 mediates neutrophil migration into the airways in response to influenza virus-induced toll-like receptor signaling. PLoS Pathog 2012, 8:e1002641.
33. Zhang J.Y., Wenzel S.E. Tissue and BAL based biomarkers in asthma. Immunol Allergy Clin North Am 2007, 27:623-632.
34. Cataldo D.D., Tournoy K.G., Vermaelen K., Munaut C., Foidart J.M., Louis R., et al. Matrix metalloproteinase-9 deficiency impairs cellular infiltration and bronchial hyperresponsiveness during allergen-induced airway inflammation. Am J Pathol 2002, 161:491-498.
35. Karakoc G.B., Yukselen A., Yilmaz M., Altintas D.U., Kendirli S.G. Exhaled breathcondensa te MMP-9 level and its relationship with asthma severity and interleukin-4/10 levels in children. Ann Allergy Asthma Immunol 2012, 108:300-304.
36. Vignola A.M., Riccobono L., Mirabella A., Profita M., Chanez P., Bellia V., et al. Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. Am J Respir Crit Care Med 1998, 158:1945-1950.
37. Erbek S.S., Yurtcu E., Erbek S., Sahin F.I. Matrix metalloproteinase-9 promoter gene polymorphism (-1562>T) in nasal polyposis. Am J Rhinol Allergy 2009, 23:568-570.
38. Inoue H., Mashimo Y., Funamizu M., Yonekura S., Horiguchi S., Shimojo N., et al. Association of the MMP9 gene with childhood cedar pollen sensitization and pollinosis. J Hum Genet 2012, 57:176-183.
39. Butler G.S., Butler M.J., Atkinson S.J., Will H., Tamura T., Schade van Westrum S., et al. The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study. J Biol Chem 1998, 273:871-880.
40. Cao J., Sato H., Takino T., Seiki M. The C-terminal region of membrane type matrix metalloproteinase is a functional transmembrane domain required for pro-gelatinase A activation. J Biol Chem 1995, 270:801-805.
41. Gohlke U., Gomis-Ruth F.X., Crabbe T., Murphy G., Docherty A.J., Bode W. The C-terminal (haemopexin-like) domain structure of human gelatinase A (MMP2): structural implications for its function. FEBS Lett 1996, 378:126-130.
42. Murphy G., Knauper V. Relating matrix metalloproteinase structure to function: why the "hemopexin" domain?. Matrix Biol 1997, 15:511-518.
43. Mishra A., Srivastava A., Mittal T., Garg N., Mittal B. Association of matrix metalloproteinases (MMP2, MMP7 and MMP9) genetic variants with left ventricular dysfunction in coronary artery disease patients. Clin Chim Acta 2012, 413:1668-1674.
44. Nan H., Niu T., Hunter D.J., Han J. Missense polymorphisms in matrix metalloproteinase genes and skin cancer risk. Cancer Epidemiol Biomarkers Prev 2008, 17:3551-3557.
45. Sharma K.L., Misra S., Kumar A., Mittal B. Higher risk of matrix metalloproteinase (MMP- 2, 7, 9) and tissue inhibitor of metalloproteinase (TIMP-2) genetic variants to gallbladder cancer. Liver Int 2012, 32:1278-1286.
46. Suchankova P., Pettersson R., Nordenström K., Holm G., Ekman A. Personality traits and the R668Q polymorphism located in the MMP-9 gene. Behav Brain Res 2012, 228:232-235.
47. Wu S., Hsu L.A., Teng M.S., Lin J.F., Chang H.H., Chang P.Y., et al. Association of matrix metalloproteinase 9 genotypes and cardiovascular disease risk factors with serum matrix metalloproteinase 9 concentrations in Taiwanese individuals. Clin Chem Lab Med 2010, 48:543-549.
48. McBrien N.A., Lawlor P., Gentle A. Scleral remodeling during the development of and recovery from axial myopia in the tree shrew. Invest Ophthalmol Vis Sci 2000, 41:3713-3719.
49. Ramírez-Bello J., Jiménez-Morales S., Espinosa-Rosales F., Gómez-Vera J., Gutierrez R., Velázquez-Cruz R., et al. Juvenile rheumatoid arthritis and asthma, but not childhood- onset systemic lupus erythematosus are associated with FCRL3 polymorphisms in Me xicans. Mol Immunol 2013, 53:374-378.
50. Yamada R., Tanaka T., Unoki M., Nagai T., Sawada T., Ohnishi Y., et al. Association between a single-nucleotide polymorphism in the promoter of human interleukin-3 gene and rheumatoid arthritis in Japanese patients, and maximum-likelihood estimation of combinatorial effect that two genetic loci have on susceptibility to the disease. Am J Hum Genet 2001, 68:674-685.
51. Fisher S.A., Hampe J., Macpherson A.J., Forbes A., Lennard-Jones J.E., Schreiber S., et al. Sex stratification of an inflammatory bowel disease genome search shows male-specific linkage to the HLA region of chromosome 6. Eur J Hum Genet 2002, 10:259-265.
52. Szczeklik W., Sanak M., Szczeklik A. Functional effects and gender association of COX- 2 gene polymorphism G-765C in bronchial asthma. J Allergy Clin Immunol 2004, 114:248-253.
53. Akkad D.A., Arning L., Ibrahim S.M., Epplen J.T. Sex specifically associated promoter polymorphism in multiple sclerosis affects interleukin 4 expression levels. Genes Immunol 2007, 8:703-706.